ArticleAnnals of medicine and surgery (2012)2026

Erratum: Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug: Erratum.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.